⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265333 | 0.94 | — | — | |
| SCHEMBL2069043 | 0.94 | — | — | |
| SCHEMBL31466817 | 0.89 | — | — | |
| Lithium SCHEMBL31375392 | 0.89 | — | — | |
| SCHEMBL28542038 | 0.89 | — | — | |
| SCHEMBL8066372 | 0.89 | — | — | |
| SCHEMBL4700450 | 0.89 | — | — | |
| SCHEMBL9840042 | 0.89 | — | — | |
| SCHEMBL12486882 | 0.89 | — | — | |
| Ammonia Solution, Strong SCHEMBL27956548 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3805232-B1 | CRYSTALLINE SYNTHETIC INTERMEDIATE USEFUL IN PROCESSES FOR MAKING A MDM2 INHIBITOR | AMGEN INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250295647-A1 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | AMGEN INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20230301974-A1 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | AMGEN INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20220280496-A1 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | AMGEN INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220280495-A1 | Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| EP-4039256-A1 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND DASATINIB OR NILOTINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA | Amgen Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3068393-B9 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3068393-B1 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3805232-A1 | CRYSTALLINE SYNTHETIC INTERMEDIATE USEFUL IN PROCESSES FOR MAKING A MDM2 INHIBITOR | Amgen Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10881648-B2 | Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20160289190-A1 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | AMGEN INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287569-A1 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289243-A1 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | AMGEN INC. (US) | 2016-10-06 | — | — | US | disclosed |
| EP-3068393-A2 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | Amgen Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160264526-A1 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | AMGEN INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-9376386-B2 | Processes of making and crystalline forms of a MDM2 inhibitor | AMGEN, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-3008039-A1 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | AMGEN, INC. (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2015070224-A2 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2014200937-A1 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140364455-A1 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | AMGEN INC. | 2014-12-11 | — | — | US | disclosed |